246 completed, 51 terminated, 32 recruiting, 26 active not recruiting. 111 Phase 2, 95 Phase 3, 41 Phase 1, 24 Phase 4, 5 Not applicable.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 2 | 111 | Completed 48, Terminated 29, Recruiting 15, Active not recruiting 9, Withdrawn 5, Unknown 4, Not yet recruiting 1 |
| Phase 3 | 95 | Completed 68, Terminated 10, Active not recruiting 8, Recruiting 4, Unknown 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 1 | 41 | Completed 24, Active not recruiting 6, Terminated 5, Recruiting 4, Withdrawn 2 |
| Phase 4 | 24 | Completed 20, Recruiting 2, Terminated 1, Withdrawn 1 |
| Not applicable | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow Ipsen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy
IPN60340 + azacitidine + venetoclax, Placebo + azacitidine + venetoclax - Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | Phase 2 / Phase 3 | Not yet recruiting | Ipsen | 540 | 2026-11-01 | 2026-09-10 |
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
Corabotase, Placebo - Moderate to Severe Glabellar Lines | Phase 3 | Recruiting | Ipsen | 160 | 2026-08-25 | 2026-09-14 |
Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy
Elafibranor - Pregnancy Related | | Recruiting | Ipsen | 3 | 2026-07-29 | 2026-10-06 |
A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Alagille Syndrome | | Recruiting | Ipsen | 30 | 2026-07-10 | 2026-10-01 |
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
Follicular Lymphoma | | Withdrawn | Ipsen | | 2026-06-01 | 2026-04-29 |
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
Elafibranor, Placebo - Primary Sclerosing Cholangitis | Phase 3 | Recruiting | Ipsen | 350 | 2026-05-14 | 2026-10-01 |
Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC)
PFIC - Progressive Familial Intrahepatic Cholestasis | | Active not recruiting | Ipsen | 200 | 2026-04-26 | 2026-10-01 |
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China
Progressive Familial Intrahepatic Cholestasis | | Recruiting | Ipsen | 20 | 2026-04-16 | 2026-10-01 |
A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours
Tovorafenib - Low-grade Glioma | Phase 1 | Active not recruiting | Ipsen | 6 | 2026-03-10 | 2026-10-01 |
Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
Surgical resection - Adenocarcinoma of the Pancreas | Not applicable | Recruiting | The University of Texas Health Science Center at San Antonio | 40 | 2026-03-02 | 2026-04-14 |
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
Corabotase, Placebo - Moderate to Severe Glabellar Lines | Phase 3 | Active not recruiting | Ipsen | 309 | 2026-02-27 | 2026-09-09 |
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
Corabotase, Placebo - Moderate to Severe Glabellar Lines | Phase 3 | Active not recruiting | Ipsen | 1300 | 2026-02-18 | 2026-10-01 |
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
IPN01203 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | Ipsen | 102 | 2026-02-06 | 2026-09-03 |
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Neuroendocrine Tumors | | Recruiting | Ipsen | 150 | 2025-12-17 | 2026-10-01 |
A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain
PFIC - Progressive Familial Intrahepatic Cholestasis | | Completed | Ipsen | 150 | 2025-12-08 | 2026-08-03 |
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
IPN60300 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | Ipsen | 114 | 2025-12-05 | 2026-10-01 |
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
Progressive Familial Intrahepatic Cholestasis | | Recruiting | Ipsen | 10 | 2025-10-30 | 2026-10-01 |
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Zanubrutinib, Rituximab, Obinutuzumab - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | University of Utah | 24 | 2025-09-12 | 2026-06-30 |
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
Tazverik (Tazemetostat) - Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Withdrawn | Epizyme, Inc. | | 2025-09-02 | 2026-01-30 |
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
Prostate Cancer, Prostate Cancer (Diagnosis) | | Recruiting | Société Algérienne de Formation et Recherche en Oncologie | 2000 | 2025-07-21 | 2026-04-17 |
Showing 20 of 379. Sign in to see all of them.
Conditions studied
Acromegaly (37) · Prostatic Neoplasms (29) · Neuroendocrine Tumors (20) · Muscle Spasticity (18) · Carcinoma, Renal Cell (16) · Torticollis (12) · Colorectal Neoplasms (7) · Liver Cirrhosis, Biliary (7) · Neoplasm Metastasis (7) · Breast Neoplasms (6) · Neoplasms (6) · Stroke (6) · Diarrhea (5) · Gastro-enteropancreatic neuroendocrine tumor (5) · Pancreatic Neoplasms (5)
Interventions
abobotulinumtoxinA (55) · Botulinum Toxins, Type A (52) · lanreotide (35) · irinotecan sucrosofate (23) · Triptorelin Pamoate (21) · cabozantinib (20) · Fluorouracil (10) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (9) · Data Collection (9) · Leucovorin (8) · Ginkgo biloba extract (7) · mecasermin (7) · Injections (6) · irosustat (6) · Smectite (5)
Countries
United States (126) · France (121) · Spain (72) · Germany (70) · United Kingdom (70) · Italy (65) · Belgium (57) · Poland (51) · Czechia (48) · Netherlands (37) · Russia (35) · Australia (27) · Canada (27) · Austria (25) · China (22)
Top investigators
Frederik Nevens, MD, PhD (3) · Joost PH Drenth, MD, PhD (2) · Loes van Keimpema, MSc (2) · Adriaan Bins, MD, PhD (1) · Afsaneh Barzi, MD (1) · Albert Font, MD (1) · Alessio Baricich (1) · Alice Wei, MD (1)
Results publications
PMID 34316644, PMID 20359934, PMID 25324317, PMID 29093068, PMID 29781237, PMID 32108436, PMID 32741133, PMID 33052555, PMID 35400537, PMID 36206385, PMID 17167516, PMID 17192294, PMID 17892497, PMID 18248639, PMID 18381583, PMID 19542735, PMID 19639415, PMID 19646443, PMID 19898989, PMID 19953707, PMID 20111849, PMID 21086246, PMID 21148630, PMID 21351269, PMID 21442656, PMID 21606412, PMID 22021883, PMID 22327622, PMID 22327623, PMID 22327624, PMID 22371239, PMID 22475206, PMID 22673486, PMID 22700836, PMID 22959217, PMID 23109694, PMID 23123438, PMID 23129737, PMID 23150706, PMID 23512837, PMID 23533264, PMID 23584301, PMID 23604344, PMID 23794582, PMID 24053191, PMID 2406025, PMID 24423301, PMID 24705026, PMID 24943105, PMID 25014687
NIH funding
2004 (11), 2019 (10), 2005 (8), 2009 (8), 2015 (8), 2023 (7), 2018 (6), 2014 (5), 2017 (5), 2016 (4), 2008 (3), 2025 (3), P30CA014089 (1), P30CA060553 (1), R21CA186140 (1)